Evidence map›Paper›PMID 35457138›Full record

ArticleInternational journal of molecular sciences2022

Diagnostic Value of MAML2 Rearrangements in Mucoepidermoid Carcinoma.

Julia C Thierauf, Alex A Farahani, B Iciar Indave, Adam Z Bard, Valerie A White, Cameron R Smith, Hetal Marble, Martin D Hyrcza, John K C Chan, Justin Bishop and 16 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 8 institutions in 5 countries.

Julia C ThieraufDepartment of Pathology, Center for Integrated Diagnostics, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Alex A FarahaniDepartment of Pathology, Center for Integrated Diagnostics, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
B Iciar IndaveInternational Agency for Research on Cancer (IARC), World Health Organization, 69372 Lyon, France.ORCID 0000-0003-0259-4781
Adam Z BardDepartment of Pathology, Center for Integrated Diagnostics, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.ORCID 0000-0003-1091-7843
Valerie A WhiteInternational Agency for Research on Cancer (IARC), World Health Organization, 69372 Lyon, France.
Cameron R SmithDepartment of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.ORCID 0000-0002-6347-7506
Hetal MarbleDepartment of Pathology, Center for Integrated Diagnostics, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Martin D HyrczaDepartment of Pathology and Laboratory Medicine, University of Calgary, Calgary, AB 2500, Canada.
John K C ChanDepartment of Pathology, Queen Elizabeth Hospital, Kowloon, Hong Kong, China.
Justin BishopDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Qiuying ShiDepartment of Pathology, Emory University Hospital, Atlanta, GA 30322, USA.
Kim ElyDepartment of Pathology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Abbas AgaimyInstitute of Pathology, Friedrich Alexander University Erlangen-Nürnberg, University Hospital, 91054 Erlangen, Germany.ORCID 0000-0002-0445-8161
Maria Martinez-LageDepartment of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Vania NoseDepartment of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Miguel RiveraDepartment of Pathology, Center for Integrated Diagnostics, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Valentina NardiDepartment of Pathology, Center for Integrated Diagnostics, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Dora Dias-SantagataDepartment of Pathology, Center for Integrated Diagnostics, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.ORCID 0000-0002-1174-3972
Salil GargDepartment of Pathology, Center for Integrated Diagnostics, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Peter SadowDepartment of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Long P LeDepartment of Pathology, Center for Integrated Diagnostics, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
William FaquinDepartment of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Lauren L RitterhouseDepartment of Pathology, Center for Integrated Diagnostics, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Ian A CreeInternational Agency for Research on Cancer (IARC), World Health Organization, 69372 Lyon, France.
A John IafrateDepartment of Pathology, Center for Integrated Diagnostics, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Jochen K LennerzDepartment of Pathology, Center for Integrated Diagnostics, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.ORCID 0000-0003-2434-4978
Harvard University · USCentre international de recherche sur le cancer · FREmory University Hospital · USFriedrich-Alexander-Universität Erlangen-Nürnberg · DEQueen Elizabeth Hospital · CNThe University of Texas Southwestern Medical Center · USUniversity of Calgary · CAVanderbilt University Medical Center · US

Funding

Strategies to Overcome Immune Resistance in Head and Neck CancersP01CA240239 · NCI · YALE UNIVERSITY · PI SARTOR, MAUREEN AGNES · 2019 to 2023
$8.4M
Illuminating the evolutionary history of colorectal cancer metastasis: basic principles and clinical applicationsR37CA225655 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI NAXEROVA, KAMILA · 2018 to 2024
$3.0M
NCI NIH HHS P01 CA240239NCI NIH HHS R37 CA225655World Health Organization 001
6 · The paper itself

Abstract

Mucoepidermoid carcinoma (MEC) is often seen in salivary glands and can harbor MAML2 translocations (MAML2+). The translocation status has diagnostic utility as an objective confirmation of the MEC diagnosis, for example, when distinction from the more aggressive adenosquamous carcinoma (ASC) is not straightforward. To assess the diagnostic relevance of MAML2, we examined our 5-year experience in prospective testing of 8106 solid tumors using RNA-seq panel testing in combinations with a two-round Delphi-based scenario survey. The prevalence of MAML2+ across all tumors was 0.28% (

Indexed as

Carcinoma, MucoepidermoidSalivary Gland NeoplasmsDNA-Binding ProteinsHumansNuclear ProteinsOncogene Proteins, FusionProspective StudiesTrans-ActivatorsTranscription FactorsTranslocation, GeneticDNA-Binding ProteinsMAML2 protein, humanNuclear ProteinsOncogene Proteins, FusionTrans-ActivatorsTranscription FactorsadenosquamousbiomarkerCRTCfusion genemolecular testingmucoepidermoidnext-generation sequencing

Identifiers

PMID35457138
PMCPMC9026998
OpenAlexW4224019317

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.